MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
Key Points
Bodenstedt sold 13,653 shares for a transaction value of ~$273,000 at around $20.02 per share on May 11, 2026.
The sale represented 1.1% of his direct holdings, reducing his direct position from 1,186,084 to 1,172,431 shares.
This was a direct-only transaction with no indirect or derivative activity, impacting solely common shares; all remaining shares are held directly.
Bodenstedt retains 1,172,431 shares (direct) after the transaction.
- 10 stocks we like better than MoonLake Immunotherapeutics ›
On May 11, 2026, MoonLake Immunotherapeutics (NASDAQ:MLTX) Chief Financial Officer Matthias Bodenstedt reported the sale of 13,653 common shares in an open-market transaction, according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 13,653 |
| Transaction value | $273,000 |
| Post-transaction shares (direct) | 1,172,431 |
| Post-transaction value (direct ownership) | $22.09 million |
Transaction value based on SEC Form 4 reported price ($20.02); post-transaction value based on May 11, 2026 market close ($18.84).
Key questions
- How material is this sale relative to Bodenstedt's total holdings?
The 13,653 shares sold accounted for only 1.1% of his direct ownership, leaving a substantial remaining position of over 1.17 million shares. - Was the transaction executed under a prearranged plan?
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. - Are there any changes to indirect or derivative holdings as a result of this transaction?
No indirect or derivative securities were involved; all shares sold and remaining are held directly, with no change to derivative exposure. - How does this transaction compare to Bodenstedt's historical trading activity?
Sell transactions over the past year have varied in size, but this disposition is smaller than his April 2026 sale and reflects a reduced capacity after prior sales, rather than a shift in trading cadence.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 6-4-2026) | $18.72 |
| Market capitalization | $1.38 billion |
| Net income (TTM) | -$257.08 million |
| 1-year price change | -63.33% |
* 1-year performance calculated using June 4, 2026 as the reference date.
Company snapshot
- Develops sonelokimab, an investigational nanobody therapy targeting inflammatory diseases, with clinical programs in hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.
- Operates as a clinical-stage biopharmaceutical company, generating value through advancing novel immunotherapeutic candidates toward regulatory approval and potential future commercialization.
- Targets healthcare providers and patients affected by chronic inflammatory and autoimmune conditions within the specialty pharmaceutical market.
What this transaction means for investors
MoonLake Immunotherapeutics’ CFO recently sold part of his stake in the company, but this isn’t a signal for investors to be concerned. It was part of a Rule 10b5-1 trading plan, a method insiders use to avoid scrutiny for improper trading. More importantly, it was just over 1% of his total shares. So, this is not necessarily a cause for concern.
But what about MoonLake? It’s considered a high-risk investment with the expectation of high reward, though many analysts have rated it a Buy. Its lead drug, sonelokimab, is showing positive results in trials and is expected to be approved for commercial launch in late 2027. This could mean significant upside for investors.
On the other hand, the company is pre-revenue, so if its drug development is not successful or is delayed, investors may be waiting a long time to reap the rewards. The stock has been volatile, rising and falling as news about its drug pipeline is released. And even if a drug under development is showing positive results in its trials, there is still no guarantee of success.
Aggressive investors who can afford to bet on high-risk stocks and can wait for long-term results may find MoonLake worth considering. Conservative investors would likely prefer to allocate their capital elsewhere.
Should you buy stock in MoonLake Immunotherapeutics right now?
Before you buy stock in MoonLake Immunotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MoonLake Immunotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,632!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,316,532!*
Now, it’s worth noting Stock Advisor’s total average return is 959% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 4, 2026.
Pamela Kock has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
